GPAtlas🧭 When to offer or consider PSA testing
Testing an asymptomatic man for prostate cancer is a shared decision-making and counselling process, not a diagnostic test or a screen. The prostate-specific antigen (PSA) blood test is offered through the Prostate Cancer Risk Management Programme (PCRMP): any asymptomatic man aged 50 and over who asks can have a free NHS PSA test after a balanced discussion of the benefits and harms. Officially, GPs are advised not to proactively raise PSA testing with average-risk asymptomatic men.
Two things have shifted the picture. The 2024 Prostate Cancer UK clinical consensus recommends a proactive discussion from age 45 in men at higher-than-average risk. And in 2026 the UK National Screening Committee (UK NSC) recommended – and the Government accepted – the UK's first prostate cancer screening programme: a targeted programme for men with a high-risk genetic profile. Population screening is still not recommended, because across the whole population the PSA test causes more harm than good.
The key primary-care skill is to identify who to test, counsel honestly on benefits and harms, and never miss a malignant prostate.
| Who | When / what to do |
|---|---|
| Average-risk man aged ≥ 50 | He can request a free NHS PSA test after a balanced discussion; current PCRMP advice is that GPs do not proactively raise it. |
| Black men (African / African-Caribbean family origin) aged ≥ 45 | Proactively discuss – lifetime risk ~1 in 4 (vs ~1 in 8 in White men), with higher mortality and more metastatic disease at diagnosis. |
| Family history of prostate cancer (first-degree relative) aged ≥ 45 | Proactively discuss; consider an earlier conversation if a relative was diagnosed young or died of the disease. |
| Pathogenic BRCA2 variant + family history of breast / ovarian / pancreatic / prostate cancer, aged 45–61 | Now eligible for the new NHS targeted screening programme – 2-yearly PSA testing (UK NSC, 2026). |
| Symptomatic man of any age (LUTS, visible haematuria, erectile dysfunction, bone pain, weight loss) | Assess and refer as a symptomatic patient under NICE NG12 – this is not screening. |
| Man aged > 79 or with limited life expectancy | PSA testing is not routine; consider only if symptomatic and fit enough for radical treatment. |
The discussion stands or falls on an honest account of what the test can and cannot do.
| Benefits to discuss | Harms to discuss |
|---|---|
|
• May detect an aggressive cancer early, when treatment can be curative or life-extending. |
• A raised PSA is often benign (benign prostatic hyperplasia, prostatitis, urinary tract infection) – causing anxiety and further tests. |
|
• A reassuringly low PSA (for example < 1 ng/mL at 60) indicates a very low long-term risk. |
• False reassurance – up to ~15% of cancers occur with a PSA in the normal range (false negatives). |
|
• The modern pathway (MRI before biopsy) has reduced – though not removed – the harms of investigation. |
• Leads to MRI ± prostate biopsy, which carries a risk of bleeding, infection and sepsis. |
|
• Overdiagnosis of a slow-growing cancer that would never have caused harm, and overtreatment side effects – urinary, bowel and erectile problems. |
Source: NICE NG12 · PCRMP · UK NSC · Prostate Cancer UK
🔒 Sign up free to read the full topic
You're viewing a free preview. Create a free account to unlock the rest.
Sign up free →Sample topics are open to everyone in the Free Sample Bundle.